Drug intelligence / Profile preview

REGN14256

Development stage: Discontinued
Lead developer: Regeneron Pharmaceuticals
Modality: Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

REGN14256 is an investigational antiviral drug developed by Regeneron Pharmaceuticals for the treatment of COVID-19 infections. It was studied in combination with imdevimab in clinical trials targeting adult and adolescent patients with COVID-19. The precise mechanism of action for REGN14256 has not been defined publicly, but it is classified as an antiviral agent. Clinical development reached phase I/II before being terminated by the sponsor in June 2023[1][2][4]. There are no approved brand names or marketed formulations for this compound.

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on REGN14256.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REGN14256.

Explore the full profile